VPC
VKTX icon

Vestal Point Capital’s Viking Therapeutics VKTX Stock Holding History

Vestal Point Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.5M Sell
680,000
-234,147
-26% -$7.56M 0.62% 39
2026
Q1 		$29.7M Buy
+914,147
New +$29.4M 0.83% 41
2024
Q2 		– Sell
-75,000
Closed -$6.15M – 77
2024
Q1 		$6.15M Buy
+75,000
New +$3.34M 0.51% 38

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vestal Point Capital's VKTX Position: Q2 2026 in Review

Vestal Point Capital reduced its Viking Therapeutics (VKTX) stake by 26% in Q2 2026, selling an estimated $7.56M and leaving 680,000 shares worth $26.5M. The position accounts for 0.62% of the portfolio, ranked #39.

Vestal Point Capital first reported a position in VKTX in Q1 2024 and has held it in 3 quarters since. The position peaked at $29.7M in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Vestal Point Capital held 680,000 shares of Viking Therapeutics worth $26.5M as of Q2 2026.
  • Vestal Point Capital sold 234,147 Viking Therapeutics shares in Q2 2026, an estimated $7.56M.
  • Viking Therapeutics made up 0.62% of Vestal Point Capital's portfolio in Q2 2026, its #39 holding.
  • Vestal Point Capital first reported a position in Viking Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Vestal Point Capital's Viking Therapeutics position peaked at $29.7M in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.